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Abstract
Thyroid disorders are more frequently observed in diabetic patients. These conditions have been shown to be mainly of autoimmune origin 
and all of them may lead to hormonal imbalance. Especially strong links exist between autoimmune thyroid diseases (AITD) and type 1 
diabetes. Importantly, both hypothyroidism and hyperthyroidism can adversely affect metabolic control of diabetes. These recommenda-
tions propose diagnostic and therapeutic algorithms for thyroid dysfunction in diabetic patients. (Endokrynol Pol 2013; 64 (1): 73–77)
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Streszczenie
Zaburzenia czynności tarczycy dotyczą znacznej części populacji osób chorych na cukrzycę. Najczęściej są to zaburzenia o podłożu autoim-
munologicznym, częściej współistniejące z cukrzycą typu 1. Zarówno niedoczynność, jak i nadczynność tarczycy pogarszają wyrównanie 
metaboliczne pacjentów z cukrzycą. Celem zaleceń było zaproponowanie algorytmu diagnostyczno-terapeutycznego chorób tarczycy 
u pacjentów z cukrzycą. (Endokrynol Pol 2013; 64 (1): 73–77)
Słowa kluczowe: choroby tarczycy, niedoczynność tarczycy, nadczynność tarczycy, cukrzyca typu 1, cukrzyca typu 2, cukrzyca przedciążowa 
Introduction
Thyroid disorders can be found in approximately 7% of 
the adult population [1]. Simultaneously, however, the 
condition is diagnosed in as much as 11% to 30% of pa-
tients with type 1 or 2 diabetes mellitus, predominantly 
females [2–4]. About 15% of type 2 diabetic patients suffer 
from overt hypothyroidism; additionally, a further 10% 
present subclinical hypothyroidism [5]. On the other 
hand, approx. 3.5% of type 2 diabetic patients are affected 
by overt hyperthyroidism, whereas 3% of that popula-
tion are diagnosed with subclinical hyperthyroidism [5]. 
Thyroid dysfunction co-occurs more often with type 1 
diabetes, and can affect as many as 30% of the patients. [6]. 
Commonest among them are autoimmune disorders 
(Hashimoto’s thyroiditis and Graves’ disease) [7]. 
The study was not financed from external sources.
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6–10% of type 1 diabetic patients are also diagnosed with 
hyperthyroidism in the course of Graves’ disease. 
Hypothyroidism is found in 17% of pregnant 
women with type 1diabetes [8]. Also, postpartum thy-
roiditis is observed three times more frequently in type 
1 diabetic patients [9]. 
Diabetes mellitus is also an important risk factor 
for cardiovascular disease. Both hypothyroidism and 
hyperthyroidism adversely affect the metabolic control 
of diabetes. Moreover, subclinical, as well as overt hypo- 
and hyperthyroidism, irrespective of the concomitant 
diabetes, can negatively affect the cardiovascular system 
[10]. As a result, diabetic patients suffering from thyroid 
disorders constitute a group with a particularly high risk 
of cardiovascular disease.
The aim of this paper was to summarise the current 
state of knowledge on diabetes and coexisting thyroid 
disorders, to propose an algorithm of assessing thyroid 
function in diabetes mellitus patients, and to offer rec-
ommendations for the management of thyroid dysfunc-
tion in the aforementioned group.
Influence of thyroid hormones  
on carbohydrate metabolism 
Thyroid hormones tend to increase the level of liver 
gluconeogenesis and glycogenolysis, as well as elevate 
lactate synthesis in muscle and fat tissue (Cori cycle). 
Additionally, liver gluconeogenesis is facilitated by 
stimulation of proteolysis in muscles, which leads to 
an increased amino acid supply to the liver. Thyroid 
hormones impact the number of GLUT2 transmem-
brane glucose transporters in hepatocytes, which also 
increases the load of glucose to the liver. Furthermore, 
elevated lipolysis during fasting causes an increase in 
the level of free fatty acids, also stimulating liver glu-
coneogenesis [11]. 
In hyperthyroidism, endogenous gluconeogenesis 
is increased and the suppressive influence of insulin on 
gluconeogenesis is significantly impaired. On the other 
hand, the increase in blood supply to tissues, including 
skeletal muscles, enhances glucose uptake. Hypergly-
caemia in hyperthyroidism is also connected with in-
creased intestinal glucose uptake, due to the enhanced 
activity of the SGLT1 Na+/glucose co-transporter in 
enterocytes.
Hyperthyroidism entails a decreased insulin half-
life, probably as a result of increased insulin degradation 
and increased release of biologically inactive precursors 
of insulin. Additionally, a decrease in the C-peptide to 
proinsulin ratio has been noted, suggesting proinsulin 
metabolism disorders. The deterioration in the meta-
bolic control of diabetes in hyperthyroidism could also 
be connected with an increase in the concentration and 
activity of hormones antagonistic to insulin — glucagon 
and catecholamines.
A reduction of both glycogenolysis in muscles 
and liver and gluconeogenesis in liver, as well as 
a decrease of both basal insulin secretion and intestinal 
glucose absorption, can be observed in hypothyroid-
ism. Consequently, the condition increases the risk of 
recurrent hypoglycaemia. Both overt and subclinical 
hypothyroidism entail an increased insulin resistance 
connected with impaired glucose uptake in peripheral 
tissues.
It has been demonstrated that levothyroxine treat-
ment normalises fasting insulinaemia and increases 
insulin sensitivity, without impacting upon glycaemia. 
It also positively influences cardiovascular disease risk 
factors, such as lipid profile, diastolic blood pressure, 
and waist-hip ratio.
Influence of diabetes mellitus  
on thyroid hormones 
Diabetic patients have been demonstrated to have 
a lower peak night TSH secretion, and an impaired 
TSH response to TRH stimulation. Patients with poor 
metabolic control (HbAlc > 10%) have presented 
inhibition of type 1 deiodinase activity, and as a re-
sult, decreased T4 to T3 conversion, lower T3 serum 
levels, and elevated rT3 concentration, which can be 
explained as the body’s defence mechanism against 
increased tissue catabolism and against decreased tis-
sue oxygen consumption [12]. 
Influence of selected drugs  
on thyroid hormones
In terms of the hormonal diagnostics of thyroid dis-
orders, it should be borne in mind that other clinical 
conditions and administered drugs influence the 
concentration of TSH and thyroid hormones [13]. Anti-
diabetic medications can also impact the hypothalamic– 
–pituitary–thyroid axis.
Studies show that metformin undergoes minimal 
biotransformation and is transported as an organic 
cation in a form not bound with proteins. It has been 
shown in an animal model that in this form it can cross 
the brain-blood barrier and its concentration in the 
hypothalamus and in the pituitary gland corresponds 
to its serum concentration [14]. In patients with type 
2 diabetes and hypothyroidism, both treated and not 
treated with levothyroxine, a significant decrease of 
TSH without change of fT4 has been observed after 
one year of treatment with metformin. A similar reac-
tion has not been noted in euthyroid diabetic patients 
treated with metformin [15]. 
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Several reports also indicate that sulfonylurea de-
rivatives can inhibit the synthesis and secretion of 
thyroid hormones, as well as displace them from the 
binding with globulin (TBG) and/or thyroxine-binding 
prealbumin (transthyretin) [13]. However, studies 
conducted with various sulfonylureas have so far not 
confirmed that these drugs have a clinically significant 
influence on thyroid function [16].
As a result, when interpreting laboratory tests for 
thyroid function in patients on anti-diabetic medica-
tions, the potential influence of metformin should 
be taken into account. Currently, however, there are 
no grounds to formulate separate monitoring and 
treatment guidelines in patients treated with oral 
anti-diabetic medications. Until now there have been 
no clear indications regarding screening tests for thyroid 
disorders in diabetic patients. Both the choice of tests 
and their frequency remain a matter of debate. 
Choice of diagnostic tests for the  
evaluation of thyroid function
Most clinical recommendations suggest measuring 
levels of TSH and anti-thyroid antibodies when diabe-
tes is newly diagnosed. Patient monitoring is based on 
controlling the TSH level. A correct TSH concentration 
has a high predictive value, and constitutes the basis 
for excluding potential thyroid disorders. In certain 
clinical situations, assessing just the TSH level may not 
be sufficient to evaluate hormonal function correctly, 
e.g. when the hypothalamic-pituitary-thyroid axis is 
disrupted, during the monitoring of hyperthyroidism 
treatment, and during pregnancy. This also pertains to 
acute diabetic complications — diabetic ketoacidosis, 
hyperglycaemic hyperosmolar state, as well as recurrent 
and acute episodes of hypoglycaemia. In such situa-
tions, in order to evaluate thyroid hormonal function 
correctly, measuring both TSH and fT4 during and after 
achieving metabolic control is recommended. Detecting 
an abnormal glycaemic profile in hyperthyroidism may 
indicate an elevated risk of developing diabetes in the 
future. Therefore, an oral glucose tolerance test should 
be performed in such patients after euthyroidism has 
been achieved.
Polish Society of Endocrinology and Polish 
Diabetes Association recommendations on 
screening for thyroid dysfunction in type 1 
and type 2 diabetes
Type 1 diabetes
1.  TSH and thyroid peroxidase antibodies (TPOAb) 
should be measured in each patient with newly 
diagnosed type 1 diabetes, and in patients who 
have never undergone tests for thyroid hormonal 
function.
2.  In patients with TPOAb titer above reference value 
and TSH concentration ≥ 2.0 mIU/L, fT4 concentra-
tion should be assessed and TSH concentration 
should be measured once a year.
3.  Patients with TPOAb titer within reference values 
and TSH ≥ 2.0 mIU/L should undergo TSH tests 
every two years.
4.  Patients with TPOAb titer within reference values 
and TSH < 2.0 mIU/L should undergo TSH tests 
every five years.
5.  Patients with family history of hypothyroidism in 
a course of chronic autoimmune thyroiditis should 
be tested for TSH level once a year.
6.  During every appointment with a diabetologist, 
patients should undergo clinical examination for 
thyroid dysfunction — in case of any abnormalities 
detected, TSH level ought to be assessed.
7.  TSH level should be measured in diabetic patients 
with a poor lipid profile. 
8.  Measurements of TSH and TPOAb titer are advis-
able in the case of every female patient planning 
a pregnancy (particularly in the case of an unfavour-
able obstetric history).
9.  Measurements of TSH and TPOAb titer are advisable 
in all female patients in the 4th–8th week of pregnancy 
(first obstetrician appointment).
10. TSH concentrations and anti-TSH receptor antibodies 
(TRAb) should be measured in all pregnant patients 
with a past medical history of Graves’ disease between 
the 4th and 8th week of pregnancy (first obstetrician 
appointment). Moreover, a second TRAb titer assess-
ment is recommended towards the end of the second 
trimester (before the 22nd week of pregnancy).
Type 2 diabetes
1.  TSH level should be measured in each patient with 
newly diagnosed type 2 diabetes, and in patients 
who have never undergone tests for thyroid hor-
monal function.
2.  Patients with TSH ≥ 2.0 mIU/L should be tested for 
TPOAb.
3.  In patients with TPOAb titer above reference value, 
diagnosis of type 2 diabetes should be reassessed 
e.g. anti-glutamic acid decarboxylase antibodies 
(anti-GAD Ab) should be measured.
4.  In patients with TPOAb titer above reference value 
and TSH concentration ≥ 2.0 mIU/L, fT4 concentra-
tion should be assessed and TSH concentration 
should be measured once a year.
5.  Patients with TPOAb titer within reference values 
and TSH ≥ 2.0 mIU/L should undergo TSH tests 
every two years.
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6.  Patients with TPOAb titer within reference values 
and TSH < 2.0 mIU/L should undergo TSH tests 
every five years.
7.  During every appointment with a diabetologist, 
patients should undergo a clinical examination for 
thyroid dysfunction — when any abnormalities are 
detected, TSH level ought to be assessed.
8.  TSH level should be measured in diabetic patients 
with a poor lipid profile. 
9.  Measurement of TSH level is advisable in the case 
of every female patient planning a pregnancy.
10. Measurements of TSH and TPOAb titer are advisable 
in all female patients in the 4th–8th week of pregnancy 
(first obstetrician appointment).
11. TSH concentrations and anti-TSH receptor anti-
bodies (TRAb) should be measured in all pregnant 
patients with a past medical history of Graves’ 
disease between the 4th and 8th week of pregnancy 
(first obstetrician appointment). Moreover, a second 
TRAb titer assessment is recommended towards the 
end of the second trimester (before the 22nd week 
of pregnancy).
Treatment
The aim of the treatment of thyroid dysfunction in 
diabetes mellitus is to achieve euthyroidism according 
to the adopted principles.
Treatment of primary hypothyroidism  
in diabetic patients
The first line treatment is a synthetic derivative of 
natural tetraiodothyronine — a medication containing 
levothyroxine sodium (LT4), in a daily dose individually 
determined for each patient. It has been demonstrated 
that subclinical hypothyroidism is an independent 
risk factor for cardiovascular episodes, which is of par-
ticular importance in the case of diabetic patients [17]. 
Therefore, treatment of subclinical hypothyroidism is 
recommended in this population. 
Pregnancy and lactation [18]
It is necessary to treat both overt and subclinical hypo-
thyroidism in pregnant patients. It should be noted that 
females with type 1diabetes — especially if an elevated 
TPOAb titer has been observed during pregnancy — are 
at a higher risk of developing postpartum thyroiditis. 
Consequently, females with type 1 diabetes should be 
tested for TSH levels six weeks, as well as three, six and 
nine months after delivery. L-thyroxine does not pass 
into breast milk, and hence there are no contraindica-
tions for breast-feeding mothers.
Treatment of primary hyperthyroidism  
in diabetic patients
The methods of treatment of hyperthyroidism both 
in the course of nodular goitre and Graves’ disease 
in diabetic patients do not differ from the commonly 
accepted ones.
Nodular goitre
The treatment of choice for hyperthyroidism resulting 
from nodular goitre, irrespective of the concomitant 
diabetes, is almost always a radical one (thyroidectomy, 
radioiodine therapy). 
Graves’ disease
The first-line therapy — as in the case of non-diabetic 
patients — entails pharmacotherapy lasting 12–24 
months (optimally 18 months). The aim of the treat-
ment is to achieve a remission. Should this goal not be 
attained, the next step is radical therapy. The method of 
choice is radioiodine therapy; if this is contraindicated, 
thyroidectomy should be considered.
Thyroid orbitopathy
Infiltrative orbitopathy is most commonly treated with 
steroids. In diabetic patients, the optic nerve is more 
frequently affected. However, administering steroids 
in patients suffering both from diabetes and thyroid 
orbitopathy adversely influences the metabolic con-
trol of diabetes. Hence, in patients treated with oral 
anti-diabetic medications, this is a common indication 
for periodic insulin therapy. In certain cases, conduct-
ing a thyroidectomy prior to the treatment should be 
considered.
Pregnancy and lactation [18]
The principles of therapy remain the same as in the case 
of non-diabetic female patients.
The aim of hyperthyroidism treatment during pregnan-
cy is to normalise the level of free thyroid hormones us-
ing as small doses of antithyroid medications as possible.
Thyroid disease and the treatment of diabetes
Subclinical forms of hypothyroidism, as well as hyper-
thyroidism, can lead to decompensation of diabetes, 
often in the form of hypoglycaemic episodes. A dete-
rioration of metabolic control of diabetes and increased 
insulin requirement can be found in patients with 
diabetes and overt hyperthyroidism, particularly those 
treated with insulin. Since hyperthyroidism is most 
often accompanied by insulin resistance, administer-
ing metformin — if no contraindications arise — may 
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be worth considering. It should be noted that hyper-
thyroidism in diabetic patients can increase the risk of 
diabetic ketoacidosis [19].
Summary
Thyroid dysfunction is more common in diabetic pa-
tients than in the general population, and can adversely 
influence the metabolic control of diabetes. Therefore, 
patients suffering both from diabetes mellitus and thy-
roid disorders should be subject to separate diagnostic-
therapeutic standards.
The presented paper
1.  Determines the principles of carrying out screening 
tests for thyroid dysfunction in type 1 and 2 diabetic 
patients, including diabetic female patients planning 
a pregnancy and during pregnancy.
2.  Stipulates the diagnostic and therapeutic guidelines 
for treating the abovementioned patients suffering 
from both subclinical and overt thyroid dysfunction, 
as well as for the necessary administration of steroids 
in thyroid orbitopathy.
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